What's Happening?
Mapi Pharma, a clinical-stage biopharmaceutical company, is exploring the establishment of a U.S.-based aseptic manufacturing facility. This initiative aims to support the company's expanding pipeline
and the growing global demand for aseptic and long-acting injectables. Mapi Pharma will present this plan at the SelectUSA Investment Summit, seeking potential partners and investors. The company specializes in long-acting injectable therapies, which are increasingly recognized for their benefits in patient adherence and consistent drug delivery. Mapi's portfolio includes long-acting formulations for central nervous system disorders and metabolic diseases, with key programs targeting schizophrenia and bipolar disorder.
Why It's Important?
The establishment of a U.S. aseptic manufacturing facility by Mapi Pharma is significant as it positions the company to better serve the largest market for aseptic and long-acting injectables. This move could enhance Mapi's ability to commercialize its products and ensure a reliable supply chain for patients worldwide. The U.S. facility would complement Mapi's existing capabilities in Israel, approved by the Israeli Ministry of Health and recognized by European regulatory authorities. By expanding its manufacturing footprint, Mapi aims to address significant unmet needs in the pharmaceutical industry, particularly in the areas of CNS and metabolic therapies.
What's Next?
Mapi Pharma is exploring a partnership-based structure for the U.S. facility, potentially forming a new entity with strategic and financial investors. The company will leverage its expertise and previous investments while seeking partners for capital investment and commercial capabilities. The SelectUSA Investment Summit will provide a platform for Mapi to engage with potential partners and discuss joint development opportunities. The company's management team will be available for one-on-one meetings to further these discussions and advance the U.S. manufacturing initiative.
